Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 431-440 of 639 results
Pharmaceutics, 2022 • January 15, 2022
The study assessed the safety and tolerability of NVP-13, an antisense oligonucleotide targeting TGFBR2, following repeated intrathecal administration in cynomolgus monkeys. Results showed that NVP-13...
KEY FINDING: NVP-13 demonstrated excellent local and systemic tolerability in cynomolgus monkeys following repeated intrathecal injections.
Frontiers in Pharmacology, 2022 • January 10, 2022
Recombinant adenoviruses (rAdVs) are commonly used vectors in gene therapy for spinal cord injury (SCI) due to their ability to transduce various cell types and provide high transgene expression. The ...
KEY FINDING: rAdV5-based vectors allow transduction of both nerve and glial cells, providing a high level of transgene expression.
Adv Healthc Mater, 2022 • May 1, 2022
The study addresses the thermal instability of ChABC, which limits its therapeutic use for CNS injuries. Machine learning was used to design copolymers that stabilize ChABC in aCSF, with promising res...
KEY FINDING: Active machine learning identified copolymers that significantly improved ChABC's thermal stability.
Scientific Reports, 2022 • January 28, 2022
The study establishes a motor nerve organoid model from human pluripotent stem cells to investigate axonal degeneration and regeneration under oxidative stress conditions. The model demonstrates that ...
KEY FINDING: Motor nerve organoids derived from human pluripotent stem cells (hPSCs) can be efficiently generated and exhibit characteristics of mature motor neurons.
ACS Chem Neurosci, 2022 • March 2, 2022
This study introduces novel small molecules, HJ-01 and HJ-02, designed to promote nerve regeneration through CSPG-containing scars by targeting PTPσ. These compounds restore nerve growth in vitro at n...
KEY FINDING: HJ-01 and HJ-02 restore sympathetic axon outgrowth over inhibitory CSPGs in a dose-dependent manner.
Scientific Reports, 2022 • February 18, 2022
The study demonstrates that phentolamine treatment enhances functional recovery after peripheral nerve injury (PNI) in mice. This includes improved motor function, protection of axon myelination, and ...
KEY FINDING: Phentolamine treatment significantly enhanced functional recovery in mice at 14 days post-injury (dpi) following peripheral nerve injury, as evidenced by improved rotarod performance and sciatic function index (SFI).
NEURAL REGENERATION RESEARCH, 2022 • October 1, 2022
This review discusses the critical roles of the mTOR pathway in axon regeneration in different types of CNS injury and demonstrates that the reactivation of this regenerative pathway can be achieved b...
KEY FINDING: mTOR signaling is the intrinsic axon regenerative pathway, and its reactivation can promote axon regeneration after adult CNS injury.
Biomolecules, 2022 • February 23, 2022
This review discusses the potential role of leukotriene signaling in the pathogenesis of Parkinson's disease (PD) and dementia with Lewy bodies (DLB), highlighting the involvement of leukotrienes in n...
KEY FINDING: Dysregulated leukotriene signaling is implicated in the pathological processes of Parkinson's disease (PD) and dementia with Lewy bodies (DLB), suggesting a potential therapeutic target.
International Journal of Molecular Sciences, 2022 • March 15, 2022
This review highlights the potential of sovateltide, a selective ETBRs agonist, as a therapeutic candidate for neurological disorders. Preclinical and clinical studies suggest its safety and efficacy ...
KEY FINDING: Sovateltide has shown promise in preclinical studies for treating cerebral stroke, Alzheimer's disease, spinal cord injury, and neonatal hypoxic-ischemic encephalopathy by promoting neuroprotection and neuroregeneration.
Nanomaterials, 2022 • March 30, 2022
This review highlights the potential of lipid-based nanomaterials in addressing bone complications, particularly bone metastasis, by offering targeted drug delivery and improved therapeutic efficacy. ...
KEY FINDING: Lipid-based nanocarriers can be modified with bisphosphonates to enhance their affinity for bone, allowing for improved drug delivery to targeted areas within the bone structure.